Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials

[1]  P. Montuschi,et al.  Long-Acting Beta-Agonists and their Association with Inhaled Corticosteroids in COPD , 2013 .

[2]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[3]  P. Montuschi,et al.  Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. , 2013, Current medicinal chemistry.

[4]  N. Hanania,et al.  Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease , 2012 .

[5]  E. Kerwin,et al.  Efficacy of Indacaterol 75 μg Once-Daily on Dyspnea and Health Status: Results of Two Double-Blind, Placebo-Controlled 12-Week Studies , 2012, COPD.

[6]  M. Malerba,et al.  Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects. , 2012, Drug discovery today.

[7]  L. Hang,et al.  Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: A 12‐week, placebo‐controlled study , 2012, Respirology.

[8]  R. Kaplan.  Short, Simple, but Still of Uncertain Value , 2012, COPD.

[9]  E. Kerwin,et al.  Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. , 2011, Clinical therapeutics.

[10]  A. Drollmann,et al.  Effect of Indacaterol on Dynamic Lung Hyperinflation and Breathlessness in Hyperinflated Patients with COPD , 2011, COPD.

[11]  P. Shekelle,et al.  Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society , 2011, Annals of Internal Medicine.

[12]  Roger Owen,et al.  Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study. , 2011, Chest.

[13]  Richard Casaburi,et al.  Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. , 2011, Respiratory medicine.

[14]  Didier Renard,et al.  Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches , 2011, Respiratory research.

[15]  H. Magnussen,et al.  Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. , 2010, Respiratory medicine.

[16]  C. Vogelmeier,et al.  Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium , 2010, Respiratory research.

[17]  H. Watz,et al.  Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone , 2010, International journal of chronic obstructive pulmonary disease.

[18]  R. Dahl,et al.  Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison , 2010, European Respiratory Journal.

[19]  J. Lötvall,et al.  Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. , 2010, American journal of respiratory and critical care medicine.

[20]  H. Magnussen,et al.  Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD , 2010, Thorax.

[21]  S. Pocock,et al.  Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. , 2009, Pulmonary pharmacology & therapeutics.

[22]  E. Carter,et al.  American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. , 2010, Chest.

[23]  A. Hmissi,et al.  Bronchodilator effects of indacaterol and formoterol in patients with COPD. , 2009, Pulmonary pharmacology & therapeutics.

[24]  Christopher B Cooper,et al.  Airflow obstruction and exercise. , 2009, Respiratory medicine.

[25]  P. Shekelle,et al.  Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians , 2007, Annals of Internal Medicine.

[26]  N. Hanania,et al.  Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. , 2007, Proceedings of the American Thoracic Society.

[27]  M. Bates,et al.  Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. , 2007, Archives of internal medicine.

[28]  P. Jones,et al.  Measuring the effects of COPD on the patient. , 2005, Respiratory medicine.

[29]  D. Mahler,et al.  The MCID of the Transition Dyspnea Index is a Total Score of One Unit , 2005, COPD.

[30]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[31]  D. Mahler,et al.  Meaningful effect size and patterns of response of the transition dyspnea index. , 2003, Journal of clinical epidemiology.

[32]  D. Mahler,et al.  Minimal important difference of the transition dyspnoea index in a multinational clinical trial , 2003, European Respiratory Journal.

[33]  G A Colditz,et al.  Understanding research synthesis (meta-analysis). , 1996, Annual review of public health.

[34]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[35]  C. Wells,et al.  The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. , 1984, Chest.